NEKTAR THERAPEUTICS's ticker is NKTR and the CUSIP is 640268108. A total of 284 filers reported holding NEKTAR THERAPEUTICS in Q4 2019. The put-call ratio across all filers is 1.03 and the average weighting 0.1%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2021 | $4,274,000 | +4.9% | 237,988 | +0.2% | 0.02% | +6.7% |
Q2 2021 | $4,076,000 | -14.3% | 237,506 | -0.1% | 0.02% | -16.7% |
Q1 2021 | $4,756,000 | +19.6% | 237,789 | +1.7% | 0.02% | +12.5% |
Q4 2020 | $3,975,000 | +2.6% | 233,840 | +0.1% | 0.02% | -11.1% |
Q3 2020 | $3,875,000 | -28.0% | 233,562 | +0.6% | 0.02% | -30.8% |
Q2 2020 | $5,379,000 | +31.5% | 232,254 | +1.4% | 0.03% | +13.0% |
Q1 2020 | $4,089,000 | -17.3% | 229,079 | 0.0% | 0.02% | +4.5% |
Q4 2019 | $4,945,000 | -30.9% | 229,079 | -41.7% | 0.02% | -35.3% |
Q3 2019 | $7,154,000 | +147.4% | 392,772 | +383.2% | 0.03% | +142.9% |
Q2 2019 | $2,892,000 | -61.3% | 81,289 | -63.5% | 0.01% | -61.1% |
Q1 2019 | $7,478,000 | +0.2% | 222,568 | -1.9% | 0.04% | -12.2% |
Q4 2018 | $7,460,000 | -31.3% | 226,947 | +27.4% | 0.04% | -19.6% |
Q3 2018 | $10,856,000 | +53.8% | 178,088 | +23.2% | 0.05% | +45.7% |
Q2 2018 | $7,057,000 | -13.6% | 144,526 | +88.0% | 0.04% | -12.5% |
Q1 2018 | $8,169,000 | – | 76,877 | – | 0.04% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Camber Capital Management LP | 3,500,000 | $60,060,000 | 2.02% |
ACT CAPITAL MANAGEMENT, LLC | 161,500 | $2,772,000 | 1.42% |
Rhenman & Partners Asset Management AB | 950,000 | $16,302,000 | 1.11% |
MAVERICK CAPITAL LTD | 5,761,073 | $98,860,000 | 0.93% |
Birchview Capital, LP | 72,000 | $1,236,000 | 0.74% |
Bellevue Group AG | 4,101,404 | $70,380,000 | 0.69% |
CM Management, LLC | 50,000 | $858,000 | 0.62% |
Duquesne Family Office | 1,000,000 | $17,160,000 | 0.42% |
OSTERWEIS CAPITAL MANAGEMENT INC | 373,368 | $6,407,000 | 0.33% |
INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 67,000 | $1,149,000 | 0.30% |